Renal DivisionKey Laboratory of Renal DiseaseKey Laboratory of Chronic Kidney Disease Prevention and Treatment (Peking University), Ministry of Education, Peking University First Hospital, Peking University Institute of Nephrology, Ministry of Health of China, Beijing, 100034, China.
Vascular Surgery Department, Xuanwu Hospital, Capital Medical University, Beijing, 100053, China.
Int Urol Nephrol. 2024 Feb;56(2):683-697. doi: 10.1007/s11255-023-03706-x. Epub 2023 Jul 19.
This study aims to present the current status and frontiers of research on COVID-19 in relation to chronic kidney disease through bibliometric analysis and visualization.
Access to information through the Web of Science Core Collection, retrieved from December 2019 to May 2023. The bibliometric visualization of countries, institutions, and keywords was analyzed using VOSviewer.
A total of 1038 publications are included. The global scientific community showed a high level of collaborative consensus. The three countries with the most publications are the USA, China, and the UK. The institution with the most publications is Harvard Medical School. The research frontier for 2020 is thrombosis, for 2021 is telemedicine, for 2022 is depression, and for 2019-2023 is the COVID-19 vaccines.
This is the first bibliometric report to establish a link between COVID-19 and CKD. The USA, China, and some European countries and their institutions are major contributors to these publications. Thrombosis, telemedicine, depression, and COVID-19 vaccines are current hot topics in the field and have the potential to shape future research trends.
通过文献计量分析和可视化，展示 COVID-19 与慢性肾脏病相关的研究现状和前沿。
通过 Web of Science 核心合集获取信息，检索时间为 2019 年 12 月至 2023 年 5 月。使用 VOSviewer 对国家、机构和关键词进行文献计量可视化分析。
共纳入 1038 篇文献。全球科学界表现出高度的合作共识。发表文献数量最多的三个国家是美国、中国和英国。发表文献数量最多的机构是哈佛医学院。2020 年的研究前沿是血栓形成，2021 年是远程医疗，2022 年是抑郁，2019-2023 年是 COVID-19 疫苗。
这是首个将 COVID-19 与 CKD 联系起来的文献计量报告。美国、中国和一些欧洲国家及其机构是这些出版物的主要贡献者。血栓形成、远程医疗、抑郁和 COVID-19 疫苗是当前该领域的热点话题，有可能塑造未来的研究趋势。
